Finland· FI-REL-REL60717
JEMPERLI
A dostarlimab product containing dostarlimab, registered in Finland by Orifarm Oy. The same ATC class is registered in 12 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Dostarlimab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF07 (dostarlimab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 8 of them publish a price we can compare per daily dose
Dostarlimab · ATC L01FF07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Dostarlimab
- Manufacturer
- Orifarm Oy
- Country
- Finland (FI)
- ATC code
- L01FF07
- ATC class
- Dostarlimab
- Defined daily dose
- 24 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- fi_myyntilupa38810010 mlEUR 6700
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dostarlimab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJEMPERLIGlaxoSmithKline Trading Services Limited, Dublin
- BelgiumJemperli 500 mgGlaxoSmithKline Trading Services
- IcelandJemperliGlaxoSmithKline Trading Services Limited
- NorwayJemperliGlaxoSmithKline Trading Services Limited
- SwedenJemperli 500 mg Koncentrat till infusionsvätska, lösningGlaxoSmithKline Trading Services Ltd
- IrelandJEMPERLI 500 mg concentrate for solution for infusionGlaxoSmithKline Trading Services Limited
- SpainJEMPERLI 500 mg CONCENTRADO PARA SOLUCION PARA PERFUSIONGlaxosmithkline Trading Services Limited
- SwitzerlandJemperli
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Jemperli
- Liechtenstein · Jemperli
- Norway · Jemperli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8672e795-b1b8-4541-a648-0ea54045e7ee GET /v1/drugs/8672e795-b1b8-4541-a648-0ea54045e7ee?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "infuusiokonsentraatti, liuosta varten",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "500 mg",
"atc_label": "dostarlimabi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/21/1538/001",
"fimea_rel_id": "REL60717",
"authorised_at": "2022-09-01"
}See everything about dostarlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.